Polygenic risk scores combine many genetic variations to estimate lifetime risk of common conditions. SIMPSi Genomics turns these insights into practical actions, supporting earlier screening and targeted prevention.
Epigenetic markers show how lifestyle, environment and ageing influence gene activity over time. SIMPSi helps patients understand how positive changes today can improve future health, strengthening prevention over late treatment.
Pharmacogenomics explains how individuals process medicines differently. SIMPSi Genomics guides safer prescribing, reduces adverse reactions and helps patients reach effective treatment more quickly.
SIMPSi Genomics connects genomic data with the SIMPSi Health platform. Insights appear alongside existing clinical information, not in a separate system. This means genomic knowledge becomes part of normal consultations, annual reviews and digital self-management journeys.
Lifelong precision health view combining genomics, epigenetics, clinical metrics.
Polygenic risk scores with predictive insights and tailored prevention plans.
Improves patient engagement and understanding of genomics.
Personalised screening and wellness plans aligned to neighbourhood pathways.
Pharmacogenomic alerts reduce harm and support value-based prescribing.
Genomics education promoting equitable understanding across diverse populations.
Secure sharing of inherited risk information supporting future generations.
Enables ethical, consented contribution of outcomes data to research.
Core SIMPSi® Suite feature, integrable with NHS and community referrals.
Inclusive tools reducing cultural and socioeconomic barriers to engagement.
SIMPSi Genomics connects genomic data with the SIMPSi Health platform. Insights appear alongside existing clinical information, not in a separate system. This means genomic knowledge becomes part of normal consultations, annual reviews and digital self-management journeys.
Patients receive understandable summaries and personalised actions. Clinicians receive concise recommendations linked to guidelines. Health systems gain population level insight to plan services and prevention programmes.
Genomics is no longer experimental. It is becoming a core component of mainstream medicine. SIMPSi Genomics ensures organisations are ready for this transition, turning national ambition into day to day reality.
Proactive, preventative and personalised precision care requires better information at the point of decision. SIMPSi Genomics provides that information in a way that works for patients, professionals and health systems alike.
